MKMarta Klarić

Marta Klarić

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marta Klarić has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recurrent Dialyzer-Associated Hypersensitivity with Complement Activation Complicated by Cardiac Arrest: A Case Report

    by Dragan Klarić, Lea Katalinić, Marta Klarić

    Background: Dialyzer-associated hypersensitivity reactions are rare but potentially life-threatening complications of hemodialysis (HD). Their pathophysiology is heterogeneous. Methods: We report a 49-year-old patient with end-stage chronic kidney disease (CKD G5), severe secondary hyperparathyroidism, poorly controlled arterial hypertension, a long history of heavy smoking, severe coronary and valvular disease, reduced left ventricular ejection fraction, renal anemia, and chronic volume overload. Results: Shortly after initiation of HD with a polysulfone dialyzer (Diacap Pro), she repeatedly developed severe dyspnea, hypoxemia, and marked hypertensive responses. Similar reactions occurred after switching to a cellulose triacetate dialyzer (Sureflux), necessitating temporary conversion to peritoneal dialysis (PD). Progressive PD ultrafiltration failure and loss of residual kidney function eventually required a return to HD. Severe reactions recurred within 15–30 min of treatment despite premedication. During the most severe episode, the patient developed profound hypoxemia (SpO2 55%), severe hypertension (up to 240/130 mmHg), ventricular tachycardia, and cardiac arrest requiring successful cardiopulmonary resuscitation. Immunological evaluation demonstrated normal total IgE (17 U/mL), decreased C3 (0.76 g/L), markedly reduced total hemolytic complement activity (CH50, 18%), and elevated IL-6 (87.5 pg/mL). Chronic HD was successfully reinitiated using an FX CorAL dialyzer with a Helixone® hydro membrane. Since its introduction, no further hypersensitivity reactions have occurred, and corticosteroid, antihistamine, and bronchodilator premedication has been discontinued. This case demonstrates severe recurrent dialyzer-associated hypersensitivity with findings suggestive of complement involvement, complicated by cardiac arrest in a patient with markedly impaired cardiovascular reserve. Conclusions: Successful long-term treatment with a hydrophilic Helixone® dialyzer highlights the importance of individualized dialyzer selection in patients with severe hypersensitivity reactions.

  • Open Access

    Crescentic Glomerulonephritis Due to Enterococcal Endocarditis

    by Dragan Klarić, Marta Žutelija, Petar Šenjug, Marta Klarić, Danica Galešić Ljubanović

    Glomerulonephritis following an enterococcal endocarditis is an extremely rare and life-threatening condition. We present the case of a 71-year-old patient with rapidly progressive glomerulonephritis following enterococcal endocarditis after surgical replacement of the aortic valve. The combination of antibiotic therapy, corticosteroid therapy and haemodialysis led to an improvement in renal function; however, the severity of cardiac deterioration resulted in a fatal outcome.


  • Open Access

    Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report

    by Nikola Zagorec, Dragan Klarić, Marta Klarić, Ivica Horvatić, Petar Šenjug, Matija Horaček, Jagoda Nikić, Danica Galešić Ljubanović, Krešimir Galešić

    Collapsing glomerulopathy (CG) or collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive disease with a high tendency of progression to end-stage renal disease due to common resistance to conventional immunosuppressants. Rituximab (RTX), a monoclonal antibody against CD20 B cells, showed some benefit in the treatment of CG. We are reporting about female patients with an idiopathic form of CG presenting with nephrotic syndrome (NS) and renal insufficiency resistant to several immunosuppressive agents such as steroids (ST), calcineurin inhibitors (CNI), and cyclophosphamide (CYC). This multidrug-resistant disease responded to RTX with complete remission. Forty-four months after initial RTX administration, a relapse of CG with severe NS and acute renal insufficiency occurred. Repeated application of RTX led to complete remission again. To the best of our knowledge, we are reporting the first case of the relapsing multidrug-resistant form of CG, which responded to RTX. Current data about the treatment of CG with RTX is lacking and is based on rare case reports and small case series. Thus, our report can contribute to determining the role of RTX in the treatment of CG.